Abstract
The JAK family of protein tyrosine kinases are now recognized as important participants in a wide range of pathologies, from cancer to inflammatory diseases. In the last decade, the drive to develop drugs targeting members of this family has begun to deliver a panel of small molecule inhibitors of JAK family members, with a range of potencies and specificities. A number of these compounds have already found widespread use as biochemical tools in the elucidation of JAK activity in specific signaling and disease processes; however, many of the first generation compounds are poorly characterized with suboptimal potencies and selectivities.Herein, we present the data for those small molecule JAK inhibitors that have been described in the peer-reviewed literature and the benefits and potential issues that may be associated with the use of these tool compounds.
| Original language | English |
|---|---|
| Title of host publication | JAK-STAT Signalling |
| Subtitle of host publication | Methods and Protocols |
| Editors | Sandra E. Nicholson, Nicos A. Nicola |
| Place of Publication | Totowa, NJ USA |
| Publisher | Humana Press |
| Pages | 99-113 |
| Number of pages | 15 |
| Edition | 1st |
| ISBN (Electronic) | 9781627032421 |
| ISBN (Print) | 9781627032414, 9781493959792 |
| DOIs | |
| Publication status | Published - 2013 |
| Externally published | Yes |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Publisher | Humana Press |
| Volume | 967 |
| ISSN (Print) | 1064-3745 |
| ISSN (Electronic) | 1940-6029 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver